×

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

Ozone Therapy

Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study. 📎

Written by CYBERMED LIFE NEWS
Attachments:
Download this file (Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis - A randomized, double-blinded, placebo-controlled study..pdf)Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis - A randomized, double-blinded, placebo-controlled study..pdf[Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study.]1056 kB
Abstract Title:

Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study.

Abstract Source:

PLoS One. 2017 ;12(7):e0179185. Epub 2017 Jul 24. PMID: 28738079

Abstract Author(s):

Carlos César Lopes de Jesus, Fânia Cristina Dos Santos, Luciana Maria Oliveira Bueno de Jesus, Iara Monteiro, Maria Sonia Sousa Castro Sant'Ana, Virginia Fernandes Moça Trevisani

Article Affiliation:

Carlos César Lopes de Jesus

Abstract:

OBJECTIVE: The aim of the trial was to determine the effectiveness of oxygen-ozone injections on knee osteoarthritis concerning pain reduction, joint functional improvement, and quality of life.

METHODS: In this randomized, double-blinded, placebo controlled clinical trial, 98 patients with symptomatic knee osteoarthritis (OA) were randomized into two groups receiving intra-articular 20μg/ml of ozone (OZ) or placebo (PBO) for 8 weeks. The efficacy outcomes for knee OA were the Visual Analogue Scale (VAS), Lequesne Index, Timed Up and Go Test (TUG Test), SF-36, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Geriatric Pain Measure (GPM).

RESULTS: After 8 weeks of treatment, ozone was more effective than the placebo: VAS [mean difference (MD) = 2.16, p<0.003 (CI 95% 0.42-3.89)], GPM [MD = 18.94, p<0.004 (CI 95% 3.43-34.44)], LEQ [MD = 4.05, p<0.001 (CI 95% 1.10-7.00)], WOMAC (P) [median of diff = 9.999, p = 0.019 (CI 95% 0.000-15.000)], WOMAC (JS) [median of diff = 12.499, p<0.001 (CI 95% 0.000-12.500)], WOMAC (PF) = [median of diff = 11.760, p = 0.003 (CI 95% 4.409-19.119)], TUG (no statistical difference) and SF-36 (FC) [(MD = -25.82, p<0.001 (CI 95% 33.65-17.99)], SF-36 (PH) [MD = -40.82, p<0.001 (CI 95% -54.48-27.17)], SF-36 (GSH) [MD = -3.38, p<0.001 (CI 95% -4.83-1.93)], SF-36 (SA) [MD = 2.17, p<0.001 (CI 95% -19.67-8.24), SF-36 (EA) [MD = -35.37, p<0.001 (CI 95% -48.86-21.89)]. Adverse events occurred in 3 patients (2 in the placebo group and 1 in the ozone group) and included only puncture accidents.

CONCLUSIONS: The study confirms the efficacy of ozone concerning pain relief, functional improvement, and quality of life in patients with knee osteoarthritis.

TRIAL REGISTRATION: International Standard Randomized Controlled Trial Number Register ISRCTNR55861167.